Antimicrobial resistance (AMR) occurs when germs like bacteria, viruses and parasites change over time and stop responding to current drug treatments. As medicines become ineffective, infections persist and the risk of severe illness or death increases. This also results in a greater chance of spreading the illness to other people.
The AMR crisis, sometimes called the silent pandemic, is considered one of the top 10 global public health threats of the 21st century.
The NRC's Human Health Therapeutics Research Centre plays a pivotal role in Canada's collaborative AMR research. With extensive expertise and a strong track record in infectious disease research, our teams are developing new technologies and platforms to provide future alternatives to antibiotics and antimicrobials.
Our expertise
Our multidisciplinary expertise allows us to advance biologic solutions targeting AMR throughout all stages of the development process:
Read about some of our work related to AMR research.
Related link(s)
Contact us
Michael McCluskie
R&D Director
Immunobiology
Telephone: 613-993-9974
Email: Michael.McCluskie@nrc-cnrc.gc.ca
Targeted industries
Biopharmaceutical, biotechnology, biomanufacturers, contract research organizations.
Features
Turning the "phage" on drug resistance
We're working to make phage therapy a practical option for infections that no longer respond to antibiotics.
NRC advances the fight against antimicrobial resistance
Our researchers are engineering innovative solutions that could redefine how we fight infections.
Persistence against antimicrobial resistance
We're playing a leading role in collaborative antimicrobial resistance research from a variety of angles.